Nephromegaly

Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals

Retrieved on: 
Tuesday, October 27, 2020
Kidney diseases, Medical specialties, Clinical medicine, Polycystic disease, Polycystic kidney disease, Autosomal dominant polycystic kidney disease, Forward-looking statement, Nephromegaly

Both manuscripts are now available online and in the Scientific Documents section of our website at https://www.eloxxpharma.com/scientific-publications/ .

Key Points: 
  • Both manuscripts are now available online and in the Scientific Documents section of our website at https://www.eloxxpharma.com/scientific-publications/ .
  • We are pleased that two manuscripts on ELX-02 and other small molecule compounds in our ERSG library have been published.
  • IND enabling preclinical studies are also underway for our library of ERSG compounds in autosomal dominant polycystic kidney disease.
  • Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.

Autosomal Dominant Polycystic Kidney Disease Pipeline Insights, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Other Health, Kidney diseases, Branches of biology, Medical specialties, Genetics, Ciliopathy, Polycystic kidney disease, Kidney, Autosomal dominant polycystic kidney disease, Polycystic disease, Autosome, Nephromegaly, Polycystin 2

A detailed picture of the Autosomal Dominant Polycystic Kidney Disease pipeline landscape is provided, which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines.

Key Points: 
  • A detailed picture of the Autosomal Dominant Polycystic Kidney Disease pipeline landscape is provided, which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines.
  • The assessment part of the report embraces in-depth Autosomal Dominant Polycystic Kidney Disease commercial assessment and clinical assessment of the Autosomal Dominant Polycystic Kidney Disease pipeline products from the pre-clinical developmental phase to the marketed phase.
  • The Autosomal Dominant Polycystic Kidney Disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Autosomal Dominant Polycystic Kidney Disease across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Autosomal Dominant Polycystic Kidney Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
    Detailed Autosomal Dominant Polycystic Kidney Disease research and development progress and trial details, results wherever available, are also included in the pipeline study.

Growth of Polycystic Kidney Disease Drugs Market to be Impacted by Favorable Reimbursement Policies | Technavio

Retrieved on: 
Tuesday, October 22, 2019
Health, Pharmaceutical, Kidney diseases, Medical specialties, Ciliopathy, Medicine, Polycystic kidney disease, Polycystic disease, Rare diseases, Kidney, Autosomal dominant polycystic kidney disease, Nephromegaly

Polycystic kidney disease drugs Market 2019-2023: Geographic Landscape

Key Points: 
  • Polycystic kidney disease drugs Market 2019-2023: Geographic Landscape
    Polycystic Kidney Disease Drugs Market 2019-2023: Type Landscape
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • Polycystic kidney disease is a devastating and rare autosomal kidney disorder, and if left untreated, it may be life-threatening.
  • Such special regulatory designations make the drug approval and launch procedures easy, which will drive the polycystic kidney disease drugs market growth during the forecast period.
  • Such favorable reimbursement policies will fuel the growth of the polycystic kidney disease drugs market.

The Global Polycystic Kidney Disease Drugs Market Set to Grow More Than 6%, 2019-2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 12, 2019
Health, Pharmaceutical, Kidney diseases, Medical specialties, Medicine, Autosomal dominant polycystic kidney disease, Polycystic kidney disease, Autosomal recessive polycystic kidney disease, Kidney, Polycystic disease, Chronic kidney disease, Nephromegaly, Medullary cystic kidney disease

Global Polycystic Kidney Disease Drugs Market: About this market

Key Points: 
  • Global Polycystic Kidney Disease Drugs Market: About this market
    The special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.
  • This polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD).
  • Our global polycystic kidney disease drugs market report looks at factors such as the high prevalence of chronic kidney diseases, special regulatory designations, and the increasing R&D for developing new drugs.
  • Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth.

The polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period

Retrieved on: 
Wednesday, July 10, 2019
Kidney diseases, Medical specialties, Medicine, Autosomal dominant polycystic kidney disease, Polycystic kidney disease, Autosomal recessive polycystic kidney disease, Kidney, Polycystic disease, Nephromegaly, Polycystic kidney disease 3

This polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD).

Key Points: 
  • This polycystic kidney disease drugs market analysis considers the revenue generation from both autosomal dominant polycystic kidney disease (ADPKD), and autosomal recessive polycystic kidney disease (ARPKD).
  • Thus, the special regulatory designations will fuel the growth of the polycystic kidney disease drugs market at a CAGR of more than 6% during the forecast period.
  • For the detailed list of factors that will drive the global polycystic kidney disease drugs market during the forecast period 2019-2023, click here.
  • Also, the polycystic kidney disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth.